Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial
Reinhard Dummer(University Hospital of Zurich), Keith T. Flaherty(Cancer Research Center), L. Andres Sirulnik, Ana Arance(Hospital Clínic de Barcelona), Mario Mandalà(University of Perugia), Gabriella Liszkay(National Institute of Oncology), Valentine Jehl(Novartis (Switzerland)), Lev Demidov(Heidelberg University), Ralf Gutzmer(University Hospitals of the Ruhr-University of Bochum), James Ford, Paolo A. Ascierto(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Dirk Schadendorf(National Center for Tumor Diseases), Ernesto Wasserman(Merus (Netherlands)), Caroline Dutriaux(Centre Hospitalier Universitaire de Bordeaux), Viviana Bozón(Array BioPharma (United States)), David Hogg(University of Leeds), Georgina V. Long(The University of Sydney), Paola Queirolo, Piotr Rutkowski(The Maria Sklodowska-Curie National Research Institute of Oncology), L. Thomas(University of Liverpool), Anna Maria Di Giacomo(University of Siena), Michele Del Vecchio(Fondazione IRCCS Istituto Nazionale dei Tumori), Marine Weill(Novartis (Switzerland)), Claus Garbe(University of Tübingen)
Cited by 491
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq
|Science|2016|5.3k
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
|New England Journal of Medicine|2010|3.5k